OTCMKTS:RZLTD Rezolute (RZLTD) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free RZLTD Stock Alerts $4.65 +0.54 (+13.14%) (As of 06/4/2024 ET) Add Compare Share Share Today's Range$4.12▼$4.7350-Day Range$2.12▼$4.1552-Week Range$16.00▼$24.05Volume546,508 shsAverage Volume4,788 shsMarket Capitalization$39.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Rezolute alerts: Email Address Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About RezoluteRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.Read More RZLTD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RZLTD Stock News HeadlinesNovember 9, 2023 | investing.comRezolute (RZLT) Earnings Dates & ReportsSeptember 3, 2023 | investing.comXilio Development Inc (XLO)August 9, 2023 | forbes.comSystems Ltd.June 1, 2023 | benzinga.comStonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye DiseaseMay 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Jazz Pharmaceuticals (JAZZ)May 12, 2023 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressMay 11, 2023 | finance.yahoo.comRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressApril 25, 2023 | finance.yahoo.comGreat news for Rezolute, Inc. (NASDAQ:RZLT): Insiders acquired stock in large numbers last yearMarch 28, 2023 | markets.businessinsider.comRezolute (RZLT) Gets a Buy from H.C. WainwrightFebruary 12, 2023 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company ProgressFebruary 10, 2023 | finance.yahoo.comRezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company ProgressFebruary 7, 2023 | benzinga.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Quotes and News SummaryFebruary 2, 2023 | finance.yahoo.comAfter losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gainNovember 10, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Rezolute (RZLT)November 1, 2022 | technews.tmcnet.comRezolute to Present at the Jefferies London Healthcare ConferenceSee More Headlines Receive RZLTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:RZLTD CUSIPN/A CIKN/A Webwww.rezolutebio.com Phone650 206 4507FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.46% Return on Assets-111.71% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book3.75Miscellaneous Outstanding Shares8,418,000Free FloatN/AMarket Cap$39.14 million OptionableNot Optionable Beta4.63 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Nevan Charles Elam (Age 53)CEO & Director Comp: $869.45kDr. Keith A. Vendola M.B.A. (Age 48)M.D., MBA, Chief Financial Officer Comp: $422.76kDr. Sankaram Mantripragada (Age 60)Chief Scientific Officer Comp: $620.76kMr. Michael R. DeperroHead of OperationsDr. Brian RobertsHead of Clinical Devel.Ms. Paula OpalHead of RegulatoryDr. Sharon Xueyan WangHead of Preclinical Devel.More ExecutivesKey CompetitorsCorvus PharmaceuticalsNASDAQ:CRVSInterCureNASDAQ:INCRI-MabNASDAQ:IMABGossamer BioNASDAQ:GOSSCytomX TherapeuticsNASDAQ:CTMXView All Competitors RZLTD Stock Analysis - Frequently Asked Questions How have RZLTD shares performed in 2024? Rezolute's stock was trading at $0.9925 at the beginning of the year. Since then, RZLTD shares have increased by 368.5% and is now trading at $4.65. View the best growth stocks for 2024 here. How do I buy shares of Rezolute? Shares of RZLTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RZLTD) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings| SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.